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Administration of influenza vaccines to the lungs could be an attractive alternative to 
conventional parenteral administration. In this study, we investigated the deposition 
site of pulmonary delivered liquid and powder influenza vaccine formulations and its 
relation to their immunogenicity and protective efficacy. In vivo deposition studies in 
cotton rats revealed that, the powder formulation was mainly deposited in the trachea 
(~65%) whereas the liquid was homogenously distributed throughout the lungs 
(~96%). In addition, only 60% of the antigen in the powder formulation was deposited 
in the respiratory tract with respect to the liquid formulation. Immunogenicity studies 
showed that pulmonary delivered liquid and powder influenza formulations induced 
robust systemic and mucosal immune responses (significantly higher by liquids than 
by powders). When challenged with a clinical isolate of homologous H1N1pdm virus, 
all animals pulmonary administered with placebo had detectable virus in their lungs 
one day post challenge. In contrast, none of the vaccinated animals had detectable 
lung virus titers, except for two out of eight animals from the powder immunized 
group. Also, pulmonary vaccinated animals showed no or little signs of infection like 
increase in breathing frequency or weight loss upon challenge as compared to animals 
from the negative control group. In conclusion, immune responses induced by liquid 
formulation were significantly higher than responses induced by powder formulation, 
but the overall protective efficacy of both formulations was comparable. Thus, 
pulmonary immunization is capable of inducing protective immunity and the site of 
antigen deposition seems to be of minor relevance in inducing protection.
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InTRoDUCTIon
Influenza is one of the major respiratory diseases with high morbidity and mortality 
1,2. Annually, influenza leads to 3-5 million hospitalizations and around 250,000-
500,000 deaths worldwide 3. It is generally recognized that vaccination is the best 
strategy to prevent the disease. Currently, most influenza vaccines are administered via 
intramuscular injection (i.m.), which can induce systemic but very little or no mucosal 
immune responses4,5. Influenza virus is mainly transmitted via the airways and replicates 
in the respiratory epithelium, thus curbing the infection at the portal of entry would be 
a beneficial approach 6,7. In addition, mucosal areas such as lungs are excellent targets 
for influenza immunization because of their large surface area, which is loaded with a 
large number of antigen presenting cells5,8. 
Targeting lungs for influenza vaccination commenced in 1960’s. It was found that 
liquid formulation pulmonary administered to human subjects was as effective as the 
traditional i.m. administered influenza vaccine in preventing illness 9–11. Most likely due 
to the complicated and laborious use of nebulizers available at that time, these studies 
were discontinued and pulmonary targeting was not investigated for a long time 12,13. 
Recently, the pulmonary route has regained attention in preclinical influenza vaccine 
research using appropriate animal models 5,14–16. Influenza vaccines for pulmonary 
administration can be formulated as liquids as well as dry powders 17.
Commonly, liquid formulations can be pulmonary administered to animals using 
the Penn-Century MicroSprayer. When enough liquid is administered using this device, 
whole lung deposition can be expected as liquids can drip down. For dry powder 
formulations, it is well known that an aerodynamic particle size of 1-5 µm is required in 
order to achieve antigen deposition in the whole lung 18,19. Our previous studies have 
shown that particles of this size distribution can be prepared by spray freeze drying 
(SFD) 5,12,13,20,21. However, we found that one of the most frequently used device that 
was available for pulmonary administration of dry powders (Penn-century insufflator) 
to experimental animals cannot efficiently de-agglomerate SFD powder particles 13,22. 
Accordingly, the particle agglomerates as dispersed by this device are relatively large 
and as such are expected to be deposited in the upper airways instead of the whole 
lung. Hence we made use of this drawback of the insufflator to achieve high deposition. 
In some pre-clinical studies, for vaccine candidates against tuberculosis, and also 
against influenza, deep lung targeting has already shown an edge over targeting upper 
parts of the respiratory tract 23,24. In the study by Minne et al. better immune responses 
were found to be elicited when liquid influenza vaccine was targeted to the deep 
lung instead of the upper or central airways. However, the deposition site of powder 
formulations and its possible effect on immune responses was not determined. Also, it 
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was not investigated whether or not the site of deposition in the respiratory tract is of 
relevance for the protective efficacy of vaccine formulations. 
Majority of the studies on pulmonary administration of influenza vaccines have 
been done in the commonly used animal model for influenza research i.e. mice. 
In contrast to mice which usually require the use of mouse adapted influenza virus 
strains for challenge 25, cotton rats are susceptible to infection by unadapted, human 
influenza virus strains (Eichelberger et al. 2004, Ottolini et al. 2005, Blanco et al. 2014). 
Disease progression in cotton rats is symptomatic and can be frequently monitored by 
measuring breathing frequency, weight loss and temperature drop 26–28. Furthermore, 
compared to mice, the larger size of cotton rats makes them less prone to potential 
mechanical damage during pulmonary delivery. In a previous study, we have 
established a cotton rat infection model for a clinical isolate of H1N1pdm virus and 
tested the efficacy of whole inactivated virus influenza vaccine (WIV) administered via 
the i.m. route (Bhide et al. unpublished data). 
The aim of the current study was to investigate whether a) cotton rats can be used 
as a model for influenza vaccination via the pulmonary route; b) difference in the site 
of deposition of liquid and dry influenza vaccine formulations has an impact on the 
immunogenicity and thus the protective efficacy of these formulations. Our results 
indicate that pulmonary delivery can successfully be done in cotton rats, with liquid 
and dry powder influenza vaccine formulations being deposited in different parts of 
the respiratory tract. Further, both liquid and powder influenza formulations had the 
potential to induce protection upon challenge with a clinically relevant virus strain.
MATeRIAlS AnD MeTHoDS 
Virus and Vaccine
NIBRG-121, a vaccine strain derived from A/California/7/2009 H1N1pdm09 virus 
obtained from NIBSC (Potters Bay, UK), was grown on embryonated chicken eggs as 
described previously 20. The virus was inactivated by overnight treatment with 0.1% 
β-propiolactone (Acros Organics, Geel, Belgium) in citrate buffer (125 mM sodium citrate, 
150 mM sodium chloride, pH 8.2) at 4°C to produce WIV. After inactivation, WIV was 
dialyzed against HNE buffer (145 mM NaCl, 5 mM Hepes, 1 mM EDTA, pH 7.4, sterilized 
by autoclaving) to completely remove β-propiolactone. Inactivation was verified by 
inoculating WIV with MDCK cells and the readout was done by hemagglutination assay 
as described before 20. The protein concentration of the obtained WIV preparation was 
determined by micro-Lowry assay. The vaccine dose was based on hemagglutinin (HA) 
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For the challenge study, a clinical isolate of A/California/2009 (E9-6714) provided by 
the Department of Clinical Virology, UMCG, Groningen, the Netherlands was used. This 
virus was grown in MDCK cells and titrated in cotton rats. This virus will be termed as A/
Cal/2009 in the following sections. 
labeling of whole inactivated influenza virus vaccine
WIV was labeled with the near infrared fluorescent dye VivoTag 680XL as per the 
manufacturer's protocol. Briefly, 3.3 mL of vaccine solution (concentration: 0.31 mg/
mL of HA) was mixed with 6.5 µL of VivoTag 680XL (concentration: 25 µg/µL) and 220 
µL of 1 M NaHCO3 solution. The mixture was incubated at room temperature for two 
hours under constant shaking. Thereafter, the unbound fluorophore was removed by 
using Zeba Spin Desalting Columns (ThermoScientific, Rockford, USA). The degree of 
labeling was calculated by determining the labeled WIV and the dye concentration at 
280 and 668 nm, respectively. To adjust for fluorophore crosstalk at 280 nm, 16% of 
the absorbance at 668 nm was subtracted from the absorbance at 280 nm. The degree 
of labeling was found to be approximately 2, which means that on average each WIV 
particle was labeled with 2 dye molecules.  
Preparation of the powders by spray freeze drying
Labeled or unlabeled WIV was spray freeze dried together with inulin (4kDa, Sensus, 
Roosendaal, The Netherlands) as lyoprotectant. Inulin powders were prepared (from 
inulin solution in water) without influenza vaccine using the similar procedure. Briefly, 
labeled and unlabeled vaccine solutions were prepared in an HA:inulin weight ratio of 
1:200 and 1:40, respectively. The HA:inulin weight ratios of 1:200 and 1:40 were based on 
a dose of 5 µg (deposition study) and 25 µg HA (immunogenicity study) in 1 mg of SFD 
powder. The vaccine solutions were sprayed into a vessel of liquid nitrogen using the 
two-fluid nozzle of the Buchi 190 Mini Spray Dryer with an inner diameter of 0.5 mm. 
The nozzle was placed approximately 5 cm above the level of liquid nitrogen. A liquid 
flow rate of 5 ml/min and an atomizing airflow of 600 Ln/h were used. Then, the frozen 
vaccine solutions were freeze dried for 48 h under the following conditions: during the 
first 24 h the shelf temperature was set at -35°C and the pressure at 0.220 mbar, after 
which the, temperature was gradually increased to 20°C and the pressure was lowered 
to 0.05 mbar during the next 24 h. The spray freeze dried vaccine formulations were 
collected in a chamber with a relative humidity ≤1% and ambient temperature. Until 
further use, the obtained powders were stored under airtight conditions.
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Characterization of vaccine powders
Particle size analysis
Laser diffraction was used for determining the primary particle size distribution of 
spray freeze dried powders. RODOS (Sympatec, Clasuthal-Zellerfeld Germany) was 
used as the disperser and a pressure of 1 bar was applied for the dispersion of the 
powder. A 100 nm (R3) lens was used. For particle size measurements with the Penn-
Century insufflator (Penn-Century, Wyndmoor, USA), the tip of the insufflator and 
microsprayer was kept at a constant distance from the laser beam by mounting them 
on an in-house mounting plate. For insufflator, an AP-1 air pump was used to deliver 
1 mL of air. The geometric particle size distributions were calculated according to the 
Fraunhofer theory. 
Scanning Electron Microscopy (SEM)
A Jeol JSM 6301-F microscope was used for scanning electron microscopy. Powders 
were placed on a double sided sticky carbon tape on a metal disc. Then, the particles 
were coated with 30 nm of gold using a Balzer’s 120B sputtering device (Balzer, Union, 
Austria). Images were taken at a magnification of 500x and 5000x.
Hemagglutination assay
The receptor binding activity of WIV after spray freeze drying (unlabeled WIV 
formulation) was assessed by the hemaglutination assay as described previously 
20. Briefly, WIV was reconstituted in PBS and 50 µl was added to 96V bottom plates 
containing 50 µl of PBS. Two fold serial dilutions were prepared after which 50 µl of 1% 
guinea pig red blood cells suspension was added to each well. Hemagglutination titers 
were read 2 hours after incubation at room temperature and are expressed as log2 of 
the highest dilution where RBC agglutination could be seen.
In vivo experiments
All animal experiments were approved by the Institutional Animal Care and Use 
Committee of the University of Groningen (IACUC-RUG), The Netherlands. Outbred 
female cotton rats at an age of 10-12 weeks were purchased from Envigo, USA. Animals 
were housed as two animals per cage and were given standard diet and water. 
Deposition study and IVIS measurements 
Cotton rats were anaesthetized using isoflurane and the anesthetized animals were 
brought to vertical position and intubated with an Autograde catheter (14G, BD, Breda, 
the Netherlands). 50 µl of liquid vaccine containing 5 µg HA was delivered through the 
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syringe (Penn-Century, Wyndmoor, USA). For powder formulations, a customized 
length Penn-Century insufflator was used to deliver 1 mg of spray freeze dried powder 
containing 5 µg HA (n = 6). Three puffs of 1 mL air were used for the dispersion of the 
powder. The tip of the dispersion device was placed just above the carina of the animals. 
Immediately after vaccine administration, cotton rats were sacrificed and lungs along 
with trachea were taken out. Lungs either as such or dissected / into lung lobes were 
placed in petri dishes and evaluated by an In-Vivo Imaging System (IVIS®  Spectrum, 
Perkin Elmer, Waltham, USA). Excitation wavelength of 675 nm was used to measure 
the fluorescent emission at 720 nm. The intensity of the emitted light (photons/s/cm2/
steradian) was quantified using Living Image Software v3.2. Fluorescent intensities of 
the vaccinated animals were corrected by subtracting the fluorescent intensities of 
untreated animals (n = 3). 
Immunization and challenge study 
For this experiment, animals were injected with implantable electronic ID transponders 
via s.c. route for identification. Weights of the cotton rats around challenge phase 
ranged between 120-150 grams. Cotton rats were vaccinated via the pulmonary route 
with influenza WIV liquid [WIV (Pul-Liq), n = 11] or 1 mg powder [WIV (Pul-Pow), n = 11] 
formulations with an antigen dose of 25 µg HA for both liquid and powder formulations. 
Cotton rats were intubated and influenza vaccine was administered similarly as 
described for the in vivo deposition study. As a gold standard, 100 µl of WIV containing 
5 µg HA in HNE buffer was administered via the intramuscular (i.m.) injection, with 50 
µl divided over both hind limbs of the animals (WIV i.m., n = 9). Animals pulmonary 
administered with 1 mg SFD inulin alone were used as negative control [inulin (Pul-
Pow), n = 9]. Animals were vaccinated twice with an interval of three weeks between 
the two vaccinations. Before challenge, three animals of the pulmonary liquid group 
died due to unknown reasons. Three weeks after the 2nd vaccination, all cotton rats 
were challenged intranasally (i.n.) with 1*107 TCID50 of A/Cal/2009 virus in 100 µl dose 
volume distributed over both nostrils using a pipette. 100 µl dose volume was chosen 
in order to cover the whole respiratory tract 31. Both vaccination and challenge were 
carried out under 5% isoflurane/O2 anesthesia. 
Sample collection 
On the day of challenge, blood was drawn from the animals by orbital puncture and 
serum was separated to evaluate humoral immune responses. One day post challenge 
animals were sacrificed [n = 5 for WIV (Pul-Liq), n = 8 for WIV (Pul-Pow), n = 6 for WIV 
(i.m.), n = 6 for inulin (Pul-Pow)].  After sacrifice, nasal and lung washes were collected in 
1 ml phosphate buffered saline (PBS) containing Complete® protease inhibitor cocktail 
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volume distributed over both nostrils using a pipette. 100 µl dose volume was chosen 
in order to cover the whole respiratory tract 31. Both vaccination and challenge were 
carried out under 5% isoflurane/O2 anesthesia. 
Sample collection 
On the day of challenge, blood was drawn from the animals by orbital puncture and 
serum was separated to evaluate humoral immune responses. One day post challenge 
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tablets (Roche, Almere, The Netherlands) through a hole made in the trachea, for the 
determination of antibody and MN titers. For virus titration, lungs were collected in 
a pre-weighed tube containing complete EPISERF medium (100 U/ml penicillin, 100 
mg/ml streptomycin, 1 M HEPES, 7.5% sodium bicarbonate, all Life TechnologiesTM BV, 
Bleiswijk, The Netherlands). The tubes with lungs were weighed again and weight of 
the lung was calculated. 
Systemic and mucosal immune responses 
IgG titers were evaluated by ELISA in serum collected on the day of challenge and in 
the lung washes. IgA antibodies were determined in lung and nasal washes collected 
from the animals sacrificed one day post challenge. ELISA was performed as described 
previously 32. IgA and IgG titers were calculated as log10 of the reciprocal of the sample 
dilution corresponding to an absorbance of 0.2 at the wavelength of 492 nm. As 
described before, the functional potential of systemic antibodies was assessed by 
microneutralization (MN) and hemagglutination inhibition (HI) assay using serum 
samples taken on the challenge day 32,33. MN titers were also determined in lung washes 
taken one day post challenge. MN titers are presented as log2 titers for individual cotton 
rats for serum MN and pooled for lung MN. For HI sera were pooled per group and also 
for MN lung lavages were pooled per group, as these samples were not enough to 
perform these assays using individual sample per animal. HI titers are presented as log2 
for pooled serum per group. Limit of detection (LoD) for IgG titers was determined by 
calculating log10 of the 1
st dilution made and the negative control samples were given a 
value corresponding to half of the LoD for calculation purposes. LoD for MN and HI was 
calculated in a similar way considering log2.
Lung virus titration
Lung virus titers were determined using lung homogenates collected one day post 
challenge as described previously 20. Briefly, lung homogenates were serially diluted 2 
fold using complete EPISERF medium and inoculated with MDCK cells. After one hour 
the medium was replaced with EPISERF containing 5 µg/ml TPCK trypsin and incubated 
for 72 hours at 37 °C, 5% CO2. Viral titers were determined by adding 1% guinea pig 
RBCs to cell supernatants and scoring hemagglutination. Virus titers are depicted as 
log10 lung virus titers per gram of lung. Limit of detection (LoD) was determined by 
calculating log10 of the 1
st dilution made and the negative control samples were given 
the value as log10 of half value of the 1
st dilution.
Assessment of Clinical symptoms 
Clinical symptoms were assessed daily for ten days after virus challenge. Briefly, upon 
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changes in weight, temperature and breathing frequency (BF) for ten days. The animals 
restrained in a pre-weighed cardboard rolls were weighed and by subtracting the 
weight of the roll, the weight of the animals were calculated. BF was measured using 
plethysmography as described previously 34. BF was defined as the number of breathes 
per minute. Temperature was measured using a DAS-7008/9 detector for s.c. injected 
electronic ID transponders, when animals were restrained (BMDS, Seaford, USA).
Statistics
Mann-Whitney U test (two tailed) was used to test if the differences between two 
groups of the cotton rats tested for different parameters were significant. A p value 
of less than 0.05 was considered significant. p values less than 0.05, 0.01 and 0.001 are 
denoted by *, ** and *** respectively. Graphs were plotted using GraphPad Prism 5 
software.
ReSUlTS
Characterization of liquid and powder influenza vaccine formulations 
The morphology of inulin, labeled and unlabeled WIV powder formulations was 
examined by scanning electron microscopy (SEM). Particle size of powder formulations 
was determined by dispersion from RODOS and dry powder insufflator. Particle size 
of liquid formulation was determined by dispersion from microsprayer. Furthermore, 
the receptor binding capacity of SFD unlabeled WIV formulation was determined by 
hemagglutination assay.
Scanning electron Microscopy (SeM)
SEM indicated that the overall shape of inulin, labeled (HA:inulin 1:200) and unlabeled 
(HA:inulin 1:40) WIV powder particles was spherical (Fig. 1a, 1b and 1c). All three powder 
formulations i.e. inulin, labeled and unlabeled WIV particles had high porosity with an 
interconnected porous structure as found before for SFD powders 12,13. Unlabeled WIV 
particles seemed to have higher porosity than labeled WIV particles (Fig. 1b, 1c). This 
could be attributed to the increased HA:inulin ratio in the unlabeled WIV formulation.
Particle size of labeled and unlabeled vaccine powders
Laser diffraction analysis of labeled, unlabeled and inulin powders revealed that 50% 
of the particles had a geometric particle size < 9 µm and 90% of the particles had a size 
< 22 µm. (Fig. 1d) Geometric particle size was used to calculate aerodynamic particle 
size using the equation:
dae = de (ρp /ρo χ )
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where dae is the aerodynamic diameter, de is the geometric particle size, ρp is the density 
of the particles (g/cm3), ρo is the unit density and χ is the dynamic shape factor.
The total solid content of the vaccine solution before spray freeze drying was 50 mg/
ml which corresponds to a density (ρp) of 0.05 g/cm
3 of SFD powder particles, assuming 
no shrinkage or expansion during processing. Taking into account the geometric 
particle size (dae), ρo (unit density: 1 g/cm
3) and χ (1 for spherical shaped particles), 
the aerodynamic particle size distribution was calculated. From the equation it was 
calculated that over 90 volume-% of the inulin, labeled and unlabeled WIV particles 
had aerodynamic particle size < 5µm, hence these particles were suitable for inhalation 
(Fig. 1e). Overall, no differences in particle size were observed by the addition of 
fluorescent dye or an increase in HA content and the particle size was comparable to 
inulin only formulation.
Particle size upon dispersion from the Penn-Century Insufflator and 
Microsprayer
The dispersing capability of the insufflator was assessed by dispersion of SFD labeled 
WIV, unlabeled WIV and inulin particles. The X10, X50 and X90 values for insufflator-
dispersed particles are shown in Fig. 1(f). The majority of the particles (X90) were found 
to be extremely large. It was found that 90% of the particles had sizes around 125 
µm for all three powder formulations i.e. inulin, labeled WIV and unlabeled WIV. The 
dispersion of powder particles of size around 125 µm indicates that the insufflator was 
inefficient in de-agglomerating SFD powder particles even with 1 mL of air. However, 
when liquid vaccine formulations were dispersed from the microsprayer, the majority 
of the droplets (X90) had a geometric particle size of ~40 µm (Fig. 1f) which was about 
three-fold smaller than that from the insufflator (120 µm). Compared to insufflator-
dispersed particles (3-140 µm), the particles dispersed by the microsprayer had a 
narrow size distribution (12-40 µm).
Hemagglutination titers
The biological activity of HA in unlabeled SFD formulation was assessed by 
determining its capacity to bind to the sialic acid receptors present on guinea pig 
RBC. The hemagglutination titers of reconstituted powder vaccine formulation were 
compared to those of the original untreated liquid WIV formulation. No difference in 
hemagglutination titers could be detected between reconstituted powder and the 
original liquid formulations, thus indicating that the hemagglutination activity was 
preserved after SFD for the unlabeled WIV formulation (Fig. 1g). 
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In vivo deposition study  
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To assess the distribution of labeled liquid and powder WIV formulations in cotton 
rats, imaging was performed on intact as well as dissected lungs using IVIS. Upon 
measurement, the total fluorescence intensity in trachea as well as lung lobes of the 
powder group was found to be ~40% lower than in the liquid group. This implies an 
incomplete deposition of the powder dose in the respiratory tract with respect to 
liquid WIV formulation. Furthermore, IVIS images of whole lungs showed distribution 
of the liquid WIV formulation throughout the lungs whereas powders seemed to be 
deposited mainly in the trachea and central parts of lungs (Fig. 2a). Upon dissection of 
the lungs into trachea and individual lung lobes, bright yellow fluorescent spots could 
be seen in lung lobes for the liquid WIV formulation and in the trachea for the powder 
WIV formulation. Further, upon quantification it was found that merely 4% of the liquid 
WIV formulation deposited in the respiratory tract remained within the trachea (Fig. 
2b), and thus that the majority of the liquid WIV formulation was distributed within 
the lung lobes (96%). However, for powders ~66% of the WIV formulation that was 
deposited in the respiratory tract was found in the trachea and only ~33% reached the 
central parts of the lung lobes (Fig. 2b). Thus, the amount of WIV that deposited in the 
lungs was about 5 times higher for the liquid than for the powder formulation.
The distribution of liquid and powder WIV formulations was further assessed by 
calculating relative dose percentages in trachea and individual lung lobes of the cotton 
rats. A relative dose percentage of 100 would imply that the dose percentage deposited 
in that lung lobe or trachea is equal to its weight percentage in relation to the total 
lung weight. Liquid WIV formulations showed a relative dose of ~13% in the trachea 
which further supports our conclusion of negligible deposition in the trachea (Fig. 2c). 
Moreover, a relative dose of ~200% was found in the left lung lobe, right superior and 
accessory lung lobe which would imply twice the deposition of dose in these (right 
superior and accessory) lung lobes compared to the right middle and right inferior lung 
lobe (Fig. 2c). The higher dose deposition in the left, right superior and accessory lung 
lobes is in line with the bright yellow fluorescent spots observed in these lobes after 
excision of the whole lung (Fig. 2a). However, for powders the trachea had a four-fold 
higher relative dose than the dose deposited in the lung lobes; a comparable but low 
relative dose percentage was found in all lung lobes (Fig. 2c). This is further in agreement 
with dark yellow spots in the trachea and comparable dark red patches visible in the 
central parts of lung lobes of animals vaccinated with powder formulation.
Systemic immune responses
To assess the systemic immune responses induced by liquid and powder WIV 
formulations upon pulmonary delivery, IgG ELISA, MN and HI were performed using 
serum samples collected three weeks after the second vaccination. All cotton rats were 
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tested seronegative for influenza specific antibodies before the start of the experiment 
(data not shown). After two vaccinations, animals from the inulin (Pul-Pow) group did 
not have any detectable serum IgG titers. Further, the IgG titers induced by pulmonary 
administered WIV were comparable to the titers induced by i.m. administered WIV (Fig. 
3a). Although IgG titers induced by WIV (Pul-Pow) were lower than the IgG titers induced 
by WIV (Pul-Liq), the difference was not significant. The functional assays, i.e. MN (Fig. 
3b) and HI (Fig. 3c) assay, showed that the antibodies generated by all three vaccine 
formulations had the potential to neutralize virus and inhibit virus hemagglutination 
in an in-vitro setting. WIV (Pul-Liq) induced significantly higher MN titers than WIV 
(Pul-Pow). Also, the HI titers of WIV (Pul-Liq) were higher than  WIV (Pul-Pow). Thus, 
pulmonary delivered liquid WIV was found to be slightly more potent in inducing 
functional systemic immune responses than the pulmonary delivered powder WIV 
formulation. 
Mucosal immune responses
To assess the mucosal immune responses induced by pulmonary delivered liquid and 
powder influenza vaccine formulations, IgA titers were determined using nasal and 
lung washes taken from animals sacrificed one day post challenge. Along with IgA, 
IgG and MN titers were also determined from lung washes. Animals administered with 
inulin (Pul-Pow) were negative for mucosal antibodies. WIV (Pul-Liq) induced nasal and 
lung IgA in all animals and IgA titers were significantly higher in this group than WIV 
(Pul-Pow) (Fig. 4a and 4b, respectively). Some cotton rats of the WIV (Pul-Pow) group 
were found to be non-responders for nasal (3/8) and lung IgA (4/8), while some of the 
animals vaccinated via i.m. route were found to have IgA in their nose (3/6) and lungs 
(4/6). However, the titers generated by WIV (i.m.) were found to be significantly lower 
than the titers generated by WIV (Pul-Liq) group in which all animals were responders. 
After pulmonary immunization, the detection of nasal antibodies can possibly be 
attributed to the migration of antigen specific B cells from the site of induction (lungs) 
to distant mucosal site (nose) 35,36. Further, WIV (i.m.) and WIV (Pul-Liq) formulations 
induced comparable IgG antibody titers in lungs (Fig. 4c). Lung IgG titers induced 
by WIV (Pul-Pow) were significantly lower than IgG titers induced by WIV (Pul-Liq). 
Moreover, mucosal antibodies in the lung washes were found to neutralize the virus 
in vitro (Fig. 4d) and the trend for these MN titers (higher for liquids than for powders) 
was similar to the trend observed in ELISA titers (Fig. 4b and 4c).  Thus, pulmonary 
delivered liquid WIV was found to be more immunogenic in inducing mucosal immune 
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lung viral load
To assess if the pulmonary delivered influenza vaccine formulations could reduce 
the viral load in the lungs after challenge, virus titration was done using the lungs of 
animals sacrificed on day one post challenge (Fig. 5). It has been shown before that lung 
virus replication peaks one day after challenge in cotton rats 27,37. In line with that, we 
could also detect virus in the lungs of animals administered with inulin (Pul-Pow) one 
day post-challenge (with mean titer of about 103.3), indicating successful infection. No 
detectable virus titers were found in the lungs of the cotton rats vaccinated with WIV 
(i.m.) and WIV (Pul-Liq). Also, six out of eight animals immunized with WIV (Pul-Pow) did 
not have any detectable virus in their lungs. However, in two WIV (Pul-Pow) immunized 
animals, virus could be detected in the lungs.  Interestingly, these two animals were the 
ones with no nasal and lung IgA antibodies and one of the two also had low serum IgG 
titers. Overall, the majority of the animals vaccinated with WIV via the pulmonary route 
did not have detectable virus in their lungs. 
Clinical symptoms
To assess the protection conferred by pulmonary delivered WIV formulations, animals 
were followed for ten days after challenge to evaluate the following clinical symptoms, 
i.e. weight loss, increase in BF, and drop in body temperature. Animals administered 
with inulin (Pul-Pow) showed a trend towards decrease in body weight after challenge, 
although it was not substantial (Fig. 6a). No or little weight loss was observed for 
animals vaccinated with WIV (i.m.) (Fig. 6b), WIV (Pul-Liq) (Fig. 6c) or WIV (Pul-Pow) (Fig. 
6d). Overall, live virus challenge did not have much influence on weight in any of the 
animals. 
Animals administered with inulin (Pul-Pow) showed an increase in BF after challenge 
for two days (Fig. 6e) after which the BF gradually decreased. Animals vaccinated with 
WIV (i.m.) (Fig. 6f), WIV (Pul-Liq) (Fig. 6g) or WIV (Pul-Pow) (Fig. 6h) showed no or very 
little increase in the BF over the period of 10 days. Days-wise BF was plotted for animals 
from all the groups for day 1 (Fig. 6i) and day 2 (Fig. 6j). A difference of ~30 breathes/
minute for day one and ~60 breathes/minute for day two was observed between 
the animals from the inulin and the pulmonary WIV groups. Hence, pulmonary 
administered WIV formulations protected cottons rats from infection induced increase 
in breathing. There was no effect of challenge on the temperature in non-vaccinated as 
well as vaccinated animals (supplementary fig. 1) 
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animals vaccinated with WIV (i.m.) (Fig. 6b), WIV (Pul-Liq) (Fig. 6c) or WIV (Pul-Pow) (Fig. 
6d). Overall, live virus challenge did not have much influence on weight in any of the 
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Animals administered with inulin (Pul-Pow) showed an increase in BF after challenge 
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minute for day one and ~60 breathes/minute for day two was observed between 
the animals from the inulin and the pulmonary WIV groups. Hence, pulmonary 
administered WIV formulations protected cottons rats from infection induced increase 
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In the current study, we showed that cotton rats can be successfully vaccinated against 
influenza via the pulmonary route. Further, it was demonstrated that pulmonary 
administered liquid WIV was predominantly deposited throughout the lungs while 
powder WIV was deposited mainly in the trachea, indicating clear differences in sites 
of deposition. Interestingly, a vaccination-challenge study revealed differences in 
particularly mucosal immune responses, but had only minor impact on protection 
upon live virus challenge.
Liquid and powder formulations were deposited in different parts of the respiratory 
tract, but both these formulations induced potent systemic immune responses. 
Besides systemic immune responses, an important aspect of mucosal vaccination 
is the induction of IgA antibody at mucosal sites 38,39. Even though in some previous 
studies with influenza vaccines, cotton rats were vaccinated via the i.n. route, mucosal 
immunity was not evaluated 40,41. Here for the first time we show that, upon pulmonary 
influenza vaccination, mucosal antibody (IgA and IgG) responses along with systemic 
immune responses can be achieved in this animal model. Overall, WIV (Pul-Liq) induced 
better immune responses than WIV (Pul-Pow) in particular in the respiratory tract.
Although differences in immune responses were obvious between animals 
vaccinated with liquid and powder formulations, protection with respect to prevention 
of clinical symptoms conferred by both these formulations was rather similar. Previous 
studies in mice have shown that mucosal antibodies (IgA and IgG) contribute to virus 
neutralization in vivo 42. In line with this, we also observed that mucosal antibodies 
induced upon pulmonary vaccination could neutralize the challenge virus in vitro, 
possibly indicating their role in the clearance of the virus at the portal of entry. The 
two animals having lung virus titers from the WIV (Pul-Pow) group had no lung and 
nasal IgA. Also, one of these two animals had no lung IgG while the other had low 
lung IgG titers. The remaining two non-responders for lung IgA from the WIV (Pul-Pow) 
group cleared virus from the lungs, which could be attributed to the presence of IgG 
antibodies in their lungs. This further supports the role of mucosal antibodies (IgA and 
IgG) in virus neutralization. 
Of the clinical symptoms assessed in the vaccinated and challenged animals, BF was 
earlier found to be the most sensitive parameter of infection (Bhide et al. unpublished 
data). It is known that virus replication in the respiratory tract leads to epithelial damage, 
which in turn causes difficulties in breathing in cotton rats 43. Most likely this causes an 
increase in BF of infected animals. However, cotton rats pulmonary administered with 
WIV (liquid or powder) showed little or no increase in BF compared to those pulmonary 
administered with inulin indicating that protection from virus replication in the lungs 
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administered with inulin indicating that protection from virus replication in the lungs 
results in normal breathing. Further, we found little effect of H1N1pdm challenge on 
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weight and no effect on the temperature of cotton rats administered with inulin (Pul-
Pow). This is also consistent with what has been observed previously; infection with 
H1N1pdm influenza virus, in contrast to infection with other influenza virus strains, does 
not affect the weight and temperature of cotton rats 28 (Bhide et al. unpublished data). 
Overall, no differences were observed in the protective efficacy (lung virus titers and 
BF) of WIV (Pul-Liq) and WIV (Pul-Pow) formulations; though a difference in deposition 
site was obvious. 
In this study, the tip of the insufflator was placed at the bifurcation of trachea i.e. 
carina, thus whole lung deposition might be expected. However, the introduction of 
1 ml of air to an already inflated lung caused a return flow of air containing powder 
particles. This return flow further most likely caused the majority of the particles to 
be deposited in the trachea. Moreover, it was visually observed that a fraction of the 
particles were even exhaled resulting in incomplete dosing. In addition, it was noticed 
that a portion of the powder remained in the insufflator after three puffs further 
reducing the delivered dose. The incomplete dosing of the powder formulation was 
further evident from the detection of reduced fluorescence intensity in the respiratory 
tract of cotton rats compared to the fluorescence intensity in liquid vaccinated group. 
Furthermore, as also reported by Murugappan et al., the insufflator was not able to break 
up agglomerates of the SFD powder into primary particles as 90 vol% of the dispersed 
particles had a geometric particle size of ~130 µm 13. This particle size corresponds to 
an aerodynamic diameter of 29 µm, which by far exceeds the required size range of 
1-5 µm for whole lung deposition. Thus, pulmonary delivery of SFD powder particles 
to cotton rats using the insufflator results in incomplete dosing and very limited whole 
lung deposition. Therefore, we utilized this inefficient de-agglomeration property 
of the insufflator to achieve powder deposition in trachea. Hence, we would like to 
emphasize this fact that, the powder deposition in trachea was due to the limitations 
of the pre-clinical device available for administration rather than the characteristics or 
the quality of formulation itself. 
By contrast, no air is used during administration of the liquid vaccine formulation 
with the microsprayer. Therefore, for the liquid formulation, no substantial return 
flow of air is expected. Furthermore, no substantial amount of liquid remained in 
the microsprayer. Thus, dosing was complete or nearly complete. The microsprayer 
produced droplets with a geometric size of 12-40 µm. As the density of the droplets 
was around 1 g/cm3, the aerodynamic diameter was similar to the geometric size, 
and thus also too large for whole lung deposition. Apparently, a volume of 50 µl was 
sufficient for a 'dripping down effect' to reach the alveolar regions of the lung. Thus, 
complete dosing of the liquid vaccine led to the induction of better immune responses 
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than powder vaccine which had the incomplete dosing problems due to the inefficient 
insufflator and return flow due to the breathing of the animals.
In order to target different parts of the respiratory tract, Minne et al. administered 
liquid formulations with different dose volumes and also positioned mice at different 
angles during administration. They reported deep lung deposition of influenza vaccine 
to be superior to deposition in the upper or central airways 24 It was speculated that an 
improved residence time of influenza antigen when targeted deep into the lungs (due 
to reduced mucociliary clearance) promotes a better immune response. However, our 
study shows that even though deposited in the trachea, WIV powder formulation had 
comparable protective efficacy as WIV liquid formulation deposited deep in the lungs. 
This could be due to the use of inulin in the WIV powder formulation; inulin might 
enhance the viscosity at the site of dissolution and thus the problem of mucociliary 
clearance might be countered. This might in turn increase the residence time and 
thereby uptake of WIV antigen by antigen presenting cells (APCs) which are abundantly 
present both in the trachea and in the lungs of rodents 44,45. Also, human trachea and 
lungs both contain a large number of dendritic cells that can take up antigens and 
transport them to the draining lymph nodes. 46–49. Thus, both these sites, trachea as well 
as lungs, could be favorable for influenza vaccine uptake to elicit a potent systemic and 
local immune response. Hence, the observed differences in immune responses could 
be predominately due to the incomplete dosing of the WIV powder as APCs are present 
in both trachea as well as lungs.
The current study demonstrates that the immune responses generated by influenza 
vaccine formulations deposited either in the trachea or deep lung can be potent 
enough to provide protection against live virus challenge. Since the site of deposition 
seems less important for the success of pulmonary influenza vaccination, we believe 
that a dry powder influenza vaccine formulation is preferable to a liquid formulation 
because of the following reasons; i) availability of better clinical devices for dispersion 
of powders: Though in this study we showed that the deposition of WIV (Pul-Pow) was 
predominantly in the trachea of cotton rats, deposition over the whole lungs might still 
be beneficial. Better lung deposition is expected in a clinical setting because better 
powder delivery devices for humans are available (Twincer, Torus). These devices work 
on the principle of active inhalation by the individual thereby preventing exhalation of 
the powder by return flow 17,50,51. Moreover, in a clinical setting the use of a dry powder 
inhaler with low retention can further resolve dosing issues associated with Penn-
insufflator; ii) long term stability: Previous studies have shown that by using appropriate 
formulation strategies, dry powder influenza vaccine formulations can be prepared 
with long term stability at room temperature 12,13,52–54. This alleviates the need of cold 
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great importance during pandemics 17. Hence, in a clinical setting pulmonary delivery 
of inhalable dry powder influenza vaccine formulations would be advantageous over 
liquid formulations.
ConClUSIon
In conclusion, we demonstrate that cotton rats can be used as a model for pulmonary 
influenza vaccination. Sites of deposition of liquid and powder influenza vaccine 
formulations were clearly different upon pulmonary delivery. However, the deposition 
site did not have a major impact on the protective efficacy of these formulations in 
cotton rats. 
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fig. 1. Characterization of liquid and powder formulations. Scanning Electron Microscopy (SEM) 
images of (a) inulin (b) labeled WIV and (c) unlabeled WIV powder formulations at 500x (left) and 
5000x (right) magnification (d) Geometric diameter of SFD inulin, labeled and unlabeled powder 
particles using RODOS as the disperser (e) Aerodynamic particle size of inulin, labeled and 
unlabeled WIV formulations (f ) Particle size after dispersion of SFD powder particles using the dry 
powder insufflator and liquid WIV particles using the microsprayer (g) Hemagglutination titers of 
liquid, reconstituted inulin powder and reconstituted unlabeled powder WIV formulations (n = 3); 
no differences were found among the triplicates within a group. Data are presented as average ± 
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images of (a) inulin (b) labeled WIV and (c) unlabeled WIV powder formulations at 500x (left) and 
5000x (right) magnification (d) Geometric diameter of SFD inulin, labeled and unlabeled powder 
particles using RODOS as the disperser (e) Aerodynamic particle size of inulin, labeled and 
unlabeled WIV formulations (f ) Particle size after dispersion of SFD powder particles using the dry 
powder insufflator and liquid WIV particles using the microsprayer (g) Hemagglutination titers of 
liquid, reconstituted inulin powder and reconstituted unlabeled powder WIV formulations (n = 3); 
no differences were found among the triplicates within a group. Data are presented as average ± 
standard error of the mean for (d), (e) and (f ) (n = 6).
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fig. 2. In vivo deposition of labeled liquid and powder WIV formulations. Cotton rats were 
vaccinated via the pulmonary route with labeled liquid and powder influenza vaccine formulations. 
Immediately after administration, animals were sacrificed and intact lungs were excised and later 
lungs were dissected into lung lobes for imaging. (a) Representative IVIS images of the intact 
(top) and dissected (bottom) lungs showing the deposition of liquid and powder WIV. Due to its 
proximity with the lungs, the heart (indicated by a yellow circle) was used as a negative control. 
(b) Percentage of the dose delivered in the trachea and five lung lobes (together) for liquid and 
powder WIV formulations relative to the total dose deposited in the respiratory tract. (c) Relative 
dose percentage in trachea and individual lung lobes for liquid and powder WIV formulations. 
Dose percentages for lung lobes were calculated as: (100-Dose deposition in trachea (%)). Relative 
dose percentages were determined as: Dose % in trachea or lung lobe/Weight % of trachea or 
lung lobe out of the total lung weight. Data are presented as average ± standard error of the 
mean (n = 6).
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fig. 3. Systemic immune responses after pulmonary immunization. Cotton rats were vaccinated 
twice on day 0 and day 21 with liquid or powder formulations of WIV. Control cotton rats received 
SFD inulin powder via pulmonary route. Three weeks after the 2nd vaccination (on the day of 
challenge), animals were bled and serum was used for determining systemic immune responses 
represented by (a) IgG titers (of individual cotton rats), (b) MN titers (of individual cotton rats) 
and (c) HI titers (sera pooled per experimental group). ELISA titers are represented as log10 titers, 
while MN and HI titers are represented as log2 titers with significance *p<0.05. LoD is represented 
by dashed line at 2.3 for IgG, 4.32 for MN and 2.59 for HI titers. Data are presented as average ± 
standard error of the mean [n = 6 for inulin (Pul-Pow), n = 6 for WIV (i.m.), n = 5 for WIV (Pul-Liq), 
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fig. 4. Mucosal immune responses after pulmonary immunization. Cotton rats were vaccinated 
twice followed by a homologous challenge with 107 TCID50/ animal of A/Cal/2009. One day post 
challenge some animals were sacrificed, nasal and lung washes were collected. Mucosal immune 
responses are represented as (a) Nose IgA titers and (b) Lung IgA titers (c) Lung IgG titers (d) MN 
titers from lung washes pooled per group. Titers are represented as log10 titers along with the 
significance indicated as *p<0.05 and **p<0.01. LoD is represented by a dashed line at 0.3 for 
both nose and lung IgA, while at 1.7 for lung IgG and at 2 for lung MN titers. Data are presented as 
average ± standard error of the mean [n = 6 for inulin (Pul-Pow), n = 6 for WIV (i.m.), n = 5 for WIV 
(Pul-Liq), n = 8 for WIV (Pul-Pow)].
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fig. 5. Effect of pulmonary vaccination on lung virus titers upon live virus challenge. Three weeks 
after the 2nd vaccination cotton rats were challenged with 107 TCID50/ animal of A/Cal/2009 virus. 
One day post challenge some animals were sacrificed and their lungs were homogenized to 
determine virus load. Virus titers are represented as log10 titers per gram of lung and significant 
differences between titers of different groups are represented as *p<0.05. LoD is represented by 
a dashed line at 1.3. Data are presented as average ± standard error of the mean [n = 6 for inulin 
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fig. 6. Effect of pulmonary vaccination on clinical symptoms after live influenza virus challenge. 
Upon vaccination and homologous live virus challenge, cotton rats were followed for 10 days for 
assessment of weight loss (a) Inulin (Pul-Pow), (b) WIV (i.m.), (c) WIV (Pul-Liq), (d) WIV (Pul-Pow). 
Also, change in the BF was evaluated for all the animals that were followed (e) Inulin (Pul-Pow), 
(f ) WIV (i.m.), (g) WIV (Pul-Liq) (h) WIV (Pul-Pow). Day wise BF was plotted for (i) day 1 and (j) day 2 
post challenge for animals in each group. Data [(i),( j)] are presented as average ± standard error 
of the mean (n = 3 for each group).
Eﬀect of pulmonary vaccinaaon on temperature aaer live inﬂuenza challenge
Supplementary fig 1. Effect of pulmonary vaccination on temperature after live influenza 
challenge
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